Fresenius Medical Care Calls for Kidney Disease Patients to Have Continued Access to Customary Care Level During the COVID-19 Crisis

What To Know

  • Frank Maddux, Global Chief Medical Officer of Fresenius Medical Care and member of the company’s Management Board, said the company stands firmly behind the clinical principle that despite the strain on healthcare resources caused by the pandemic, patients with End-Stage Kidney Disease requiring dialysis should be able to continue with their prescribed dialysis treatment frequency.
  • The Global Medical Advisory on Apportioning Care outlines the company’s position on how care should be allotted during and after the pandemic and addresses the differing care standards being articulated by various healthcare systems, groups and governments.

Fresenius Medical Care, a provider of dialysis products and services, has released an advisory calling for clinical care principles on access to be upheld for patients with advanced chronic kidney disease if a surge in COVID-19 infections overwhelms the available supply of facilities, caregivers and ventilators.

The Global Medical Advisory on Apportioning Care outlines the company’s position on how care should be allotted during and after the pandemic and addresses the differing care standards being articulated by various healthcare systems, groups and governments. It stresses the company’s commitment to maintaining uninterrupted healthcare delivery for patients around the world who require renal replacement therapy during the pandemic.

The advisory recognizes that capacity issues may become overwhelming to healthcare systems during the pandemic. However, it calls on “all authorities to recognize the need to make critical equipment, supplies, facilities and care delivery available to patients with advanced kidney diseases that need lifesaving therapy at all times, including during this COVID-19 disease pandemic.”

Dr. Frank Maddux, Global Chief Medical Officer of Fresenius Medical Care and member of the company’s Management Board, said the company stands firmly behind the clinical principle that despite the strain on healthcare resources caused by the pandemic, patients with End-Stage Kidney Disease requiring dialysis should be able to continue with their prescribed dialysis treatment frequency. Furthermore, dialysis access surgery or interventions needed by some patients are “not elective procedures and should be delivered in a timely manner” to prevent potential complications, he added.

The advisory asserts that patients needing renal replacement therapy during the pandemic should still be offered the appropriate treatment that has been agreed in consultation with their physicians. “These discussions may include mechanical ventilation, dialysis, continuous renal replacement therapies and any other extracorporeal support” advised by a patient’s care team, it states.

“People with advanced kidney disease come in varied degrees of health and functional status, but they all want to be productive and active members of their families and communities, and we are doing everything in our power to support their desire for individual choices on the level of care they receive,” said Dr. Maddux. “We want to avoid population-based decisions on care that may not be in the best interests of the individual person.”

Global Medical Advisory on Apportioning Care available here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy